newsfilter
← Latest News
GlobeNewswire·

Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Portfolio Execution

– ARCALYST® (rilonacept) Q4 2025 and full year 2025 net product revenue of $202.1 million and $677.6 million, respectively –– ARCALYST 2026 net product revenue expected to be $900 - $920 million –– KPL-387 Phase 2